Moderna Swings to 3Q Profit, Lifts Outlook as Covid-19 Vaccine Demand Stabilizes — Update

Morningstar · 2026-11-06 12:48 UTC

Moderna returned to profitability in the recent quarter and lifted its full-year revenue forecast, defying Wall Street expectations of continued losses as international demand for its Covid-19 shots stabilized.

By Xavier Martinez and Connor Hart

Moderna returned to profitability in the recent quarter and lifted its full-year revenue forecast, defying Wall Street expectations of continued losses as international demand for its Covid-19 shots stabilized.

The biopharmaceutical company on Friday reported a third-quarter profit of $162 million, compared with a loss of $200 million a year earlier. Quarterly earnings came out to 38 cents a share. Analysts polled by FactSet had expected a loss of $1.10 a share.

Read the full story at Morningstar · All coverage of this story